Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Field
-
if they: - Are under 26 years old - Hold a PhD that is relevant to the role - Have held a Student or Graduate visa in the last 2 years - Are already in the UK with a Tier 2 or Skilled Worker visa issued before April 4th
-
application tool. The call will remain open until a suitable candidate is identified. Make sure that your application includes: A detailed CV A one-page summary of past research activities (e.g. in PhD/PostDoc
-
Postdoctoral Research Associate - Basic and Translational Research Training in Pediatric Classical H
St. Jude is seeking outstanding candidates for postdoctoral fellowship positions in pediatric classical hematology. Research areas of interest include hematopoiesis, hemostasis/thrombosis, and non
-
collaborators working on theory and experiments As a formal qualification, you must hold a PhD degree (or equivalent). We offer DTU is a leading technical university globally recognized for the excellence of its
-
synthetic microorganisms to detect and destroy bacterial and fungal pathogens selectively. SynThera consortium contains ten research groups and is coordinated by Prof. Dr. Kai Papenfort and Prof. Dr. Miriam
-
the majority are international and the working language is English. The research group of Mikkel H. Schierup currently employs six postdocs and six PhD students in a variety of projects in evolutionary genomics
-
A postdoc position is available in the lab of Dr. Taosheng Chen Drug toxicity and resistance are the leading causes of therapeutic failures. The Chen Lab ( https://www.stjude.org/research/labs/chen
-
Postdoctoral Research Associate - Training in Pediatric Cancer Survivorship Outcomes and Interventio
St. Jude is seeking outstanding candidates for postdoctoral fellowship positions in pediatric cancer survivorship research. As a fellow, you will benefit from access to unique datasets and expertise
-
, immunometabolism and cancer immunology, by focusing on metabolic regulation of the immune system and the therapeutic impacts on cancer and other diseases. As metabolic pathways are inextricably connected to immunity
-
discovered the first CYP3A5-selective inhibitor and its structural basis (J Am Chem Soc 143:18467, 2021). Our goal is to understand nuclear receptor-regulated transcription networks, enzyme-drug interactions